A clinical trial to study the effect of Triphala,Musta,Chitraka Ghana capsules in Prediabetes in Overweight subjects.
Phase 2
- Registration Number
- CTRI/2020/06/025997
- Lead Sponsor
- Own Funded
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
HOMA IR:HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE-METHOD FOR ASSESSING B-CELL FUNCTION AND INSULIN RESISTANCE(IR)FROM BASAL(FASTING)GLUCOSE AND INSULIN OR C-PEPTIDE CONCENTRATION.
BMI >25
Exclusion Criteria
Sujects who are under OHA/Steroids/Lipid Lowering Agents
Pregnant or Lactating woman
Patients with Chronic Alcoholism
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction In HOMA-IRTimepoint: In 30 Days
- Secondary Outcome Measures
Name Time Method Reduction in BMI,Ama Lakshana,Sthaulya LakshanaTimepoint: In 30 Days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Triphala-Musta-Chitraka Ghana's effects on insulin resistance in Sthaulya-related prediabetes?
How does Triphala-Musta-Chitraka Ghana compare to metformin in improving insulin sensitivity in overweight prediabetic patients?
Which biomarkers predict response to Triphala-Musta-Chitraka Ghana in CTRI/2020/06/025997 for Sthaulya-related insulin resistance?
What adverse events are associated with Triphala-Musta-Chitraka Ghana in CTRI/2020/06/025997 overweight prediabetic subjects?
Are there synergistic effects of Triphala-Musta-Chitraka Ghana with other Ayurvedic or synthetic agents in managing prediabetes?